ONCS
Income statement / Annual
Last year (2022), OncoSec Medical Incorporated's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, OncoSec Medical Incorporated's net income was -$34.18 M.
See OncoSec Medical Incorporated’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
07/31/2022 |
07/31/2021 |
07/31/2020 |
07/31/2019 |
07/31/2018 |
07/31/2017 |
07/31/2016 |
07/31/2015 |
07/31/2014 |
07/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$25.82 M
|
$34.10 M
|
$25.10 M
|
$18.45 M
|
$17.42 M
|
$11.95 M
|
$14.74 M
|
$13.13 M
|
$5.80 M
|
$3.16 M
|
| General & Administrative
Expenses |
$11.19 M
|
$14.28 M
|
$18.31 M
|
$11.97 M
|
$18.69 M
|
$9.50 M
|
$12.14 M
|
$8.11 M
|
$6.15 M
|
$3.91 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.19 M
|
$14.28 M
|
$18.31 M
|
$11.97 M
|
$18.69 M
|
$9.50 M
|
$12.14 M
|
$8.11 M
|
$6.15 M
|
$3.91 M
|
| Other Expenses |
$28,857.00 |
-$704.00 |
$185,052.00 |
$440,037.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$37.01 M |
$48.38 M |
$43.41 M |
$30.42 M |
$36.11 M |
$21.45 M |
$26.89 M |
$21.24 M |
$11.95 M |
$7.06 M |
| Cost And Expenses |
$37.01 M |
$48.38 M |
$43.41 M |
$30.42 M |
$36.11 M |
$21.45 M |
$26.89 M |
$21.24 M |
$11.95 M |
$7.06 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$20,925.00 |
$15,857.00 |
$5,114.00 |
$3,805.00 |
$6.37 M |
$0.00 |
$0.00 |
$0.00 |
$20,684.00 |
$83,215.00 |
| Depreciation &
Amortization |
$1.10 M
|
$1.08 M
|
$1.18 M
|
$683,749.00
|
$3.67 M
|
$379,988.00
|
$355,583.00
|
$664,596.00
|
$780,110.00
|
$736,875.00
|
| EBITDA |
-$35.92 M
|
-$47.30 M
|
-$42.23 M
|
-$29.73 M
|
-$32.43 M
|
-$21.07 M
|
-$26.89 T
|
-$21.24 B
|
-$11.95 B
|
-$7.06 B
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$501,720.00
|
$800,144.00
|
$283,074.00
|
$141,922.00
|
-$3.03 M
|
$0.00
|
$0.00
|
$0.00
|
-$20,684.00
|
-$83,215.00
|
| Income Before Tax |
-$37.51 M |
-$47.58 M |
-$43.13 M |
-$30.27 M |
-$39.14 M |
-$21.45 M |
-$26.89 M |
-$21.24 M |
-$11.97 M |
-$7.15 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$3.33 M |
-$2.41 M |
-$872,585.00 |
$1,297.00 |
$680.00 |
$1,391.00 |
$2,462.00 |
$1,969.00 |
$41,773.00 |
$2,000.00 |
| Net Income |
-$34.18 M |
-$45.17 M |
-$42.25 M |
-$30.28 M |
-$39.14 M |
-$21.45 M |
-$26.89 M |
-$21.24 M |
-$12.01 M |
-$7.15 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-19.13 |
-30.2 |
-56.22 |
-94.43 |
-214.59 |
-233.73 |
-358.2 |
-367.73 |
-277.38 |
-295.25 |
| EPS Diluted |
-19.13 |
-30.2 |
-56.22 |
-94.43 |
-214.59 |
-233.73 |
-358.2 |
-367.73 |
-277.38 |
-295.25 |
| Weighted Average Shares
Out |
$1.79 M
|
$1.50 M
|
$751,570.00
|
$320,603.00
|
$182,378.00
|
$91,771.00
|
$75,066.00
|
$57,768.00
|
$43,305.00
|
$24,217.00
|
| Weighted Average Shares
Out Diluted |
$1.79 M
|
$1.50 M
|
$751,570.00
|
$320,603.00
|
$182,378.00
|
$91,771.00
|
$75,066.00
|
$57,768.00
|
$43,305.00
|
$24,217.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
